AIMS: To investigate whether or not there is a correlation between failure to respond to typical antipsychotics and CYP2D6 ultrarapid metaboliser status. METHODS: CYP2D6 phenotype (metaboliser status) was assigned following genotyping for gene duplication, as well as for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 null alleles in 235 treatment-refractory patients and 73 nonrefractory patients. RESULTS: Four (1.7%) of the 235 treatment-refractory subjects were positive on the duplication assay, but, of these, two were found to represent duplications of a null allele (CYP2D6*4 ), therefore leaving only two (0.85%) positive for duplication of a wild type allele (ultrarapid metabolisers). Three (4.1%) of the nonrefractory subjects had a genotype consistent with ultrarapid metaboliser status. Fisher's exact test gave a two-tailed P value of 0.091, i.e. a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, which was in the opposite direction to that predicted by our hypothesis. CONCLUSIONS: Although the results show a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, the percentages in the two groups of patients are both within the range for ultrarapid metabolisers in Caucasian populations. Our data are not consistent with ultrarapid metaboliser status being a major cause of failure to respond to typical antipsychotics.
AIMS: To investigate whether or not there is a correlation between failure to respond to typical antipsychotics and CYP2D6 ultrarapid metaboliser status. METHODS:CYP2D6 phenotype (metaboliser status) was assigned following genotyping for gene duplication, as well as for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 null alleles in 235 treatment-refractory patients and 73 nonrefractory patients. RESULTS: Four (1.7%) of the 235 treatment-refractory subjects were positive on the duplication assay, but, of these, two were found to represent duplications of a null allele (CYP2D6*4 ), therefore leaving only two (0.85%) positive for duplication of a wild type allele (ultrarapid metabolisers). Three (4.1%) of the nonrefractory subjects had a genotype consistent with ultrarapid metaboliser status. Fisher's exact test gave a two-tailed P value of 0.091, i.e. a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, which was in the opposite direction to that predicted by our hypothesis. CONCLUSIONS: Although the results show a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, the percentages in the two groups of patients are both within the range for ultrarapid metabolisers in Caucasian populations. Our data are not consistent with ultrarapid metaboliser status being a major cause of failure to respond to typical antipsychotics.
Authors: C von Bahr; G Movin; C Nordin; A Lidén; M Hammarlund-Udenaes; A Hedberg; H Ring; F Sjöqvist Journal: Clin Pharmacol Ther Date: 1991-03 Impact factor: 6.875
Authors: B S Chakraborty; J W Hubbard; E M Hawes; G McKay; J K Cooper; T Gurnsey; E D Korchinski; K K Midha Journal: Eur J Clin Pharmacol Date: 1989 Impact factor: 2.953
Authors: Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink Journal: Eur J Clin Pharmacol Date: 2013-07-07 Impact factor: 2.953
Authors: Wim J Tamminga; Johan Wemer; Berend Oosterhuis; Anthonius de Boer; Stan Vranckx; Ben F H Drenth; Rokus A de Zeeuw; Lou F M H de Leij; Jan H G Jonkman Journal: Eur J Clin Pharmacol Date: 2003-03-18 Impact factor: 2.953
Authors: Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison Journal: J Psychopharmacol Date: 2014-03-04 Impact factor: 4.153